Last reviewed · How we verify
NCT04939324: ExOnSite-Pro
Molecular Profiling of Exosomes in Tumor-draining Vein of Early-staged Lung Cancer
NA trial testing Blood samples at 2 sites: peripheral vein and tumor-draining vein in Lung Cancer in 30 participants. Status unknown.
21 August 2023
Quick facts
| Lead sponsor | University Hospital, Limoges |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 30 |
| Start date | 21 June 2021 |
| Primary completion | 21 August 2023 |
| Estimated completion | 6 June 2024 |
| Sites | 1 location across France |
Drugs / interventions tested
- Blood samples at 2 sites: peripheral vein and tumor-draining vein — full drug profile →
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
- Exosomes — all drugs for Exosomes →
- Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
Sponsor
University Hospital, Limoges
Who can join
18 and older, any sex, with Lung Cancer or Exosomes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observational prospective single-center study of 30 patients operated for early-staged non-small cell lung cancer. The main aim is the analysis of molecular profiling of exosome with a sample in tumor-draining vein in order to identify prognostic molecular characteristics associated with cancer recurrence after surgery.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling.
Paskeh MDA, Entezari M, Mirzaei S, Zabolian A, et al · · 2022 · cited 398× · PMID 35765040 · DOI 10.1186/s13045-022-01305-4 -
Strategies to overcome the main challenges of the use of exosomes as drug carrier for cancer therapy.
Hussen BM, Faraj GSH, Rasul MF, Hidayat HJ, et al · · 2022 · cited 71× · PMID 36258195 · DOI 10.1186/s12935-022-02743-3 -
Extracellular vesicles: A dive into their role in the tumor microenvironment and cancer progression.
Lopez K, Lai SWT, Lopez Gonzalez EJ, Dávila RG, et al · · 2023 · cited 49× · PMID 37025182 · DOI 10.3389/fcell.2023.1154576 -
Therapeutic role of mesenchymal stem cell-derived exosomes in respiratory disease.
Zargar MJ, Kaviani S, Vasei M, Soufi Zomorrod M, et al · · 2022 · cited 42× · PMID 35550188 · DOI 10.1186/s13287-022-02866-4 -
Insight into the Functional Dynamics and Challenges of Exosomes in Pharmaceutical Innovation and Precision Medicine.
Sharma A, Yadav A, Nandy A, Ghatak S. · · 2024 · cited 40× · PMID 38931833 · DOI 10.3390/pharmaceutics16060709 -
Extracellular Vesicles and Exosomes: Novel Insights and Perspectives on Lung Cancer from Early Detection to Targeted Treatment.
Rahimian S, Najafi H, Afzali B, Doroudian M. · · 2024 · cited 40× · PMID 38255228 · DOI 10.3390/biomedicines12010123 -
Harnessing exosomes as cancer biomarkers in clinical oncology.
Ghosh S, Rajendran RL, Mahajan AA, Chowdhury A, et al · · 2024 · cited 31× · PMID 39113040 · DOI 10.1186/s12935-024-03464-5 -
The Landscape of Exosomes Biogenesis to Clinical Applications.
Al-Madhagi H. · · 2024 · cited 28× · PMID 38681093 · DOI 10.2147/ijn.s463296
Verify or expand the search:
- PubMed search for NCT04939324
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other University Hospital, Limoges trials
Trials by the same sponsor.
- NCT07407101 — Impact of Filtration on Autologous Serum Eye Drops · NA · not yet recruiting
- NCT07406425 — Evaluation of Efficacy of Coconut Oil Mouth Care for Non-autonomous Hospitalised Elderly People. · NA · not yet recruiting
- NCT07436780 — B Lymphocyte Populations in the Pulmonary Microenvironment of Patients Under Mechanical Ventilation With or Without VAP · not yet recruiting
- NCT07331298 — Apparent Diffusion Coefficient of the Intervertebral Disc in Children: Pilot Study · not yet recruiting
- NCT07019818 — Esmolol Versus Sufentanil on the Quality of Post-cholecystectomy Recovery Laparoscopic Anaesthesia With Orotracheal Intu · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04939324 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Limoges
- Last refreshed: 10 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04939324.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing